Mario Sznol
0000-0002-4359-8749
Publication & Citation Trends
Publications
0 total
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study
Cited by 0
Semantic Scholar
Ex vivo expansion of melanoma tumor infiltrating lymphocytes leads to a dominant exhausted T cell population with lack of memory markers.
Cited by 0
Semantic Scholar
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Cited by 7
Semantic Scholar
Abstract CT198: A first-in-human study evaluating safety, tolerability and efficacy of TEV-56278, as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic solid tumors
Cited by 0
Semantic Scholar
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Cited by 3
Semantic Scholar
Role of high-dose interleukin-2 for melanoma in the age of cellular therapy
Cited by 6
Semantic Scholar
A Phase 3 trial of fianlimab + cemiplimab versus pembrolizumab in patients with previously untreated, unresectable, locally advanced or metastatic melanoma OA
Cited by 1
Semantic Scholar
LZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis
Cited by 2
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(314)
CAR-T cell therapy research
(170)
Immunotherapy and Immune Responses
(124)
Melanoma and MAPK Pathways
(75)
Renal cell carcinoma treatment
(51)
Affiliations
University of Toledo Medical Center
Novartis (Switzerland)
Tufts Medical Center
Roswell Park Comprehensive Cancer Center
St. Michael's Hospital